open access

Vol 45, No 1 (2011)
OPIS PRZYPADKU
Submitted: 2010-04-07
Get Citation

Inclusion body myositis: therapeutic approaches. A case report

Biruta Kierdaszuk1, Anna Kamińska1
DOI: 10.1016/S0028-3843(14)60062-1
·
Neurol Neurochir Pol 2011;45(1):68-73.
Affiliations
  1. Katedra i Klinika Neurologii w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

open access

Vol 45, No 1 (2011)
OPIS PRZYPADKU
Submitted: 2010-04-07

Abstract

Inclusion body myositis (IBM) seems to be the most common acquired myopathy among patients of age 50 or over. The characteristic clinical features of IBM include involvement of the quadriceps as well as distal muscles, mainly foot extensors and deep finger flexors. The course of the disease is slow but steadily progressive and most patients after 5 to 10 years require the aid of an assistive device. What distinguishes IBM from other inflammatory myopathies is its resistance to corticosteroids and other immunotherapies.

We present a case report, the first in the Polish population, of a male patient with a 10-year history of inclusion body myositis responding well to intravenous immunoglobulin (IVIG) therapy. Despite the almost 10 years duration of the disease, its course was slowly progressive and rather stable. Essential aspects of diagnosis and pathogenesis as well as the therapeutic approach adopted are also discussed.

Abstract

Inclusion body myositis (IBM) seems to be the most common acquired myopathy among patients of age 50 or over. The characteristic clinical features of IBM include involvement of the quadriceps as well as distal muscles, mainly foot extensors and deep finger flexors. The course of the disease is slow but steadily progressive and most patients after 5 to 10 years require the aid of an assistive device. What distinguishes IBM from other inflammatory myopathies is its resistance to corticosteroids and other immunotherapies.

We present a case report, the first in the Polish population, of a male patient with a 10-year history of inclusion body myositis responding well to intravenous immunoglobulin (IVIG) therapy. Despite the almost 10 years duration of the disease, its course was slowly progressive and rather stable. Essential aspects of diagnosis and pathogenesis as well as the therapeutic approach adopted are also discussed.

Get Citation

Keywords

inclusion body myositis, inflammatory myopathies, immunoglobulin, muscle biopsy

About this article
Title

Inclusion body myositis: therapeutic approaches. A case report

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 45, No 1 (2011)

Pages

68-73

Page views

208

Article views/downloads

603

DOI

10.1016/S0028-3843(14)60062-1

Bibliographic record

Neurol Neurochir Pol 2011;45(1):68-73.

Keywords

inclusion body myositis
inflammatory myopathies
immunoglobulin
muscle biopsy

Authors

Biruta Kierdaszuk
Anna Kamińska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl